Zacks Research Issues Positive Outlook for JAZZ Earnings

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) – Analysts at Zacks Research increased their Q1 2027 EPS estimates for shares of Jazz Pharmaceuticals in a research note issued on Monday, February 2nd. Zacks Research analyst Team now expects that the specialty pharmaceutical company will earn $3.82 per share for the quarter, up from their prior estimate of $3.80. The consensus estimate for Jazz Pharmaceuticals’ current full-year earnings is $16.96 per share.

A number of other research firms also recently weighed in on JAZZ. Piper Sandler reaffirmed an “overweight” rating and set a $219.00 price objective (up from $147.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, December 10th. UBS Group reissued a “neutral” rating and issued a $188.00 target price (up from $163.00) on shares of Jazz Pharmaceuticals in a report on Monday, November 24th. JPMorgan Chase & Co. cut their target price on Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating for the company in a research report on Monday, October 27th. Wells Fargo & Company upped their price target on Jazz Pharmaceuticals from $170.00 to $235.00 and gave the company an “overweight” rating in a research report on Tuesday, November 18th. Finally, TD Cowen reiterated a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Thursday, January 29th. Fourteen investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Jazz Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $205.67.

Jazz Pharmaceuticals Stock Performance

NASDAQ JAZZ opened at $165.72 on Tuesday. The stock has a market cap of $10.07 billion, a P/E ratio of -27.30, a PEG ratio of 0.90 and a beta of 0.26. The company’s 50-day simple moving average is $168.36 and its 200 day simple moving average is $144.82. Jazz Pharmaceuticals has a twelve month low of $95.49 and a twelve month high of $182.99. The company has a quick ratio of 1.44, a current ratio of 1.65 and a debt-to-equity ratio of 1.09.

Insiders Place Their Bets

In related news, Director Heather Ann Mcsharry sold 3,415 shares of the company’s stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $177.78, for a total transaction of $607,118.70. Following the transaction, the director owned 20,449 shares in the company, valued at $3,635,423.22. This represents a 14.31% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Rick E. Winningham sold 5,500 shares of the firm’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $180.86, for a total transaction of $994,730.00. Following the completion of the sale, the director owned 8,893 shares of the company’s stock, valued at $1,608,387.98. The trade was a 38.21% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 123,791 shares of company stock valued at $21,991,850 over the last three months. Company insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of JAZZ. Cardinal Capital Management boosted its position in Jazz Pharmaceuticals by 0.5% in the 4th quarter. Cardinal Capital Management now owns 14,538 shares of the specialty pharmaceutical company’s stock valued at $2,471,000 after buying an additional 66 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in shares of Jazz Pharmaceuticals by 9.0% during the third quarter. EverSource Wealth Advisors LLC now owns 983 shares of the specialty pharmaceutical company’s stock valued at $130,000 after acquiring an additional 81 shares during the period. Tectonic Advisors LLC increased its position in Jazz Pharmaceuticals by 1.5% in the third quarter. Tectonic Advisors LLC now owns 5,626 shares of the specialty pharmaceutical company’s stock worth $742,000 after purchasing an additional 82 shares during the period. Teacher Retirement System of Texas raised its holdings in Jazz Pharmaceuticals by 0.6% during the 2nd quarter. Teacher Retirement System of Texas now owns 15,560 shares of the specialty pharmaceutical company’s stock worth $1,651,000 after purchasing an additional 90 shares during the last quarter. Finally, Fairbanks Capital Management Inc. lifted its position in Jazz Pharmaceuticals by 0.4% during the 3rd quarter. Fairbanks Capital Management Inc. now owns 25,023 shares of the specialty pharmaceutical company’s stock valued at $3,298,000 after purchasing an additional 94 shares during the period. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals News Roundup

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Zacks raised its FY2027 EPS estimate to $20.06 (from $19.95), signaling stronger long‑term earnings expectations. MarketBeat Report
• Positive Sentiment: Zacks increased Q4 2027 EPS to $5.50 (from $5.45), a small lift that supports the FY2027 upgrade. MarketBeat Report
• Positive Sentiment: Zacks nudged up Q3 2027 to $5.70 (from $5.66) and Q2 2027 to $5.04 (from $5.03), indicating incremental confidence in mid‑2027 results. MarketBeat Report
• Positive Sentiment: Zacks raised Q4 2026 to $5.00 (from $4.96) and Q1 2027 to $3.82 (from $3.80), small upward tweaks to near‑term quarters. MarketBeat Report
• Negative Sentiment: Zacks trimmed Q3 2026 slightly to $5.25 (from $5.26) and cut Q2 2026 to $4.88 (from $4.90), modest downgrades to some nearer‑term quarters. MarketBeat Report
• Negative Sentiment: Zacks also nudged Q4 2025 down to $5.15 (from $5.16); these cuts are very small but contribute to the mixed picture. MarketBeat Report

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.